Displaying drugs 14951 - 14975 of 15222 in total
CRx-401
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … lipid profiles, and this dose has proven to be well tolerated in clinical trials. ... in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and …
(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium
Experimental
Immucillin-G
Experimental
Motexafin lutetium
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
CRA-9334
Experimental
Alphamethadol
Experimental
Illicit
3-Amino-4-Oxybenzyl-2-Butanone
Experimental
Phenylacetaldehyde
Experimental
Benzylamine
Experimental
1,3-Dinitrobenzene
Experimental
Para-Bromobenzyl Alcohol
Experimental
4-Fluorobenzylamine
Experimental
3-Iodo-Benzyl Alcohol
Experimental
3,3',5,5'-tetrachlorobiphenyl-4,4'-diol
Experimental
4-(trifluoromethyl)phenol
Experimental
2-Iodobenzylthio Group
Experimental
N-phenylthiourea
Experimental
Displaying drugs 14951 - 14975 of 15222 in total